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ABSTRACT 
The increased participation by females in athletics over the past decade, both 
competitively and leisurely, has brought attention to the number and severity of acquired 
injuries. Females tend to suffer a greater number of injuries than their male counterparts, 
and low back pain is also more prevalent in this population. Research is just beginning to 
focus on female athletes as their own separate entity. The female reproductive hormones 
have been targeted as a possible cause of many injuries secondary to the chemical and 
physical changes that occur with their fluctuations. 
The purpose of this literature review is to identify the effects of the female steroid 
hormones on low back pain and injuries that occur in the female athlete. This is 
accomplished by reviewing the physiology of the female hormonal cycles, the 
involvement of the hormones with low back pain in the athletic population, and relating 
the presence or absence of endogenous hormones to injury rate. 
The findings conclude that significant research is still required in this area of 
study before further conclusions may be drawn. This review will benefit therapists in the 
post-injury and preventative treatment of athletes as programs are designed for female 
patients with athletic injuries. 
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CHAPTER I 
INTRODUCTION 
Over the years, a large increase has been seen in the number of female 
participants in athletics, as well as an increase in the availability of women's sporting 
events. Since much of this participation includes competitive events, the amount and 
intensity of training has increased, as well. 1,2 This, in tum, has focused attention on the 
number and severity of injuries incurred by females as compared to their male 
counterparts. 1,3-6 Women athletes also tend to have a higher incidence of low back 
(lumbopelvic) pain, as well as an increased tendency to require treatment for low back 
pain.3,7 
As the apparent difference in injury rates between male and female athletic 
participants is noted, questions arise as to the possible causes or determinants of this 
problem. Researchers have initiated studies of the female athlete as a separate entity. 
Suspected influences on the rates of traumatic injury and low back pain include structural 
differences between males and females and the effects of female reproductive hormones. 
As physical therapists, it is important to apply the limited information available on this 
subject to treating female clients who suffer sports related injuries, or are involved in 
athletics, and also to aid in the prevention of such injuries. 
The purpose of this literature review is to identify the effects of the female steroid 
hormones on low back pain and injuries that occur in the female athlete. When 
discussing the honnonal influence on injuries and low back pain in female athletes, a 
review of the female reproductive cycles is helpful for a more complete understanding of 
the physiology. This literature review presents an overview of the anatomy and 
physiology of the female reproductive cycle. The available research is also presented on 
the effects or influences of the female sex honnones on low back pain and other injuries 
that occur in the female athlete. 
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CHAPTER II 
PHYSIOLOGICAL REVIEW OF THE FEMALE REPRODUCTIVE CYCLE 
The human reproductive system involves a complex interaction of several tissues 
and chemical messengers, known as hormones. Regulated by the brain, reproductive 
organs, and hormones secreted by the endocrine system, the female body experiences a 
monthly cycle beginning at puberty with the event of the first menses and continuing 
until menopause.8 An understanding of the physiology of this system is important in 
recognizing the many effects of the hormones' actions on the female body. 
There are two cycles involved in the female reproductive system, the menstrual 
cycle and the ovarian cycle. These cycles are closely interrelated and are regulated by the 
same hormones, but are also somewhat independent in their activities and functions. The 
cycles and their hormones will each be discussed separately before discussion of their 
complex interrelations (refer to Figure 1). 
Menstrual Cycle 
The human menstrual cycle typically begins between the ages of twelve and 
fifteen and endures until about forty-five to fifty years of age.9 The menstrual cycle 
pertains to the cyclic proliferation and shedding that the lining of the uterus, or 
endometrium, undergoes on a monthly basis.8 The endometrium consists of epithelium 
and lamina propria.9 The endometrial layer has two zones, the functionalis and the 
basalis. The functional is is sloughed off and replaced during each cycle, and the basalis 
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Figure 1. The menstrual and ovarian cycles. (Adapted from Litwack G. 
Biochemistry of hormones I: peptide hormones. In: Textbook of 
Biochemistry: With Clinical Correlations. 3rd ed. New York, NY: 
Wiley-Liss, Inc; 1992:876-881.) 
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is the portion retained to proliferate and provide new epithelium and lamina propria in 
order to renew the endometrium. The beginning of the cycle is marked by the onset of 
menstrual flow. 
The duration of the menstrual cycle varies, but usually averages approximately 
twenty-eight days.9 The cycle consists of three phases referred to as the menstrual, 
proliferative, and secretory phases.8- IO The menstrual phase occurs on the first through 
fourth days of the cycle, the proliferative phase occurs from the fifth to fourteenth days, 
and the secretory phase occurs during the fifteenth to twenty-eighth days (in a twenty-
eight day cycle). The duration of each phase is variable, with the proliferative phase 
being the most variable of all the phases. The difference in the length of this phase 
accounts for the difference in the lengths of cycles, both in the same individual and 
between individuals.9,lo 
The three phases represent different stages within the endometrium. The 
menstrual phase begins with the flow of the menses.8-1O A degenerating endometrium 
mixed with blood from ruptured vessels in the uterine lining comprises the menstrual 
discharge.9 During the proliferative phase, cellular proliferation and reconstitution of 
glands and surface epithelium lining the endometrium continues, as does the growth of 
the endometrium as a whole.9,1O The secretory phase is the most constant in duration. As 
this phase progresses, the endometrium reaches maximum thickness before it is shed, and 
once again the cycle renews. 
Ovarian Cycle 
The ovarian cycle is associated with the maturation of oocytes. IO It also has three 
phases, which coincide with the menstrual cycle phases.8- IO The phases are known as the 
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menstrual phase, preovulatory or follicular phase, and the postovulatory or luteal phase. 
At the beginning of the menstrual phase, about twenty follicles begin to develop 
in the ovaries. 10,1 I As the cycle moves into the preovulatory phase, the follicles (known 
as secondary follicles) continue to mature until one follicle (the largest) eventually 
becomes dominant, and the other follicles cease growth. 
During the end of the preovulatory phase, the fully mature, dominant follicle 
ruptures and expulses a secondary oocyte, or ovum. 10,1 I This is known as ovulation and 
occurs on the fourteenth day of a twenty-eight day cycle. 
The postovulatory phase begins after ovulation.9,10 At this time, the ruptured 
mature follicle develops into a corpus luteum. The corpus luteum functions to maintain 
the endometrium for implantation of a fertilized ovum. If fertilization fails to occur, the 
corpus luteum will cease to sustain the endometrial lining. This sets the course for a new 
cycle to begin. 
The menstrual and ovarian cycles are regulated by several hormones of the 
endocrine system. The hormones involved carry out complex functions and necessitate 
further discussion. 
Hormones 
The functions of the various tissues of the human body are integrated and 
controlled by the nervous system (the brain) and the hormones synthesized and released 
by the endocrine system.9 The female reproductive system is regulated primarily by the 
hypothalamus. The hypothalamus is located at the basal region of the brain and is 
concerned with the control of many major functions ofthe body.12 Hormones produced 
and released by the hypothalamus directly affect two major glands associated with the 
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female reproductive system, which include the anterior pituitary gland (located inferior to 
the hypothalamus) and the ovaries. Both structures are considered endocrine glands, in 
that the honnones produced are secreted directly into the blood stream to be carried to 
specific receptor sites on cells contained on target organs throughout the body. The 
binding of the honnones to the cells' receptors results in control of the affected cells' 
activities. Within the reproductive organs, the honnones are crucial to the necessary 
growth, development, and functioning of the reproductive system. 
The pituitary gland, which consists of an anterior and posterior portion, is 
honnonally regulated by the hypothalamus. 12 The hypothalamus, itself, produces and 
secretes a substance known as gonadotropin-releasing honnone (GnRH). Seven 
honnones are secreted by the pituitary including the following: growth honnone, thyroid 
stimulating honnone, adrenocorticotropic honnone, melanocyte-stimulating hormone, 
prolactin, follicle-stimulating honnone (FSH), and luteinizing honnone (LH). The three 
honnones concerned with the reproductive system are prolactin, FSH and LH. The latter 
two are known as gonadotropins due to their regulation of reproductive organ activity. 
Two additional honnones also contribute significant influence upon the 
reproductive cycle, estrogen and progesterone.8,12,13 They are produced primarily by the 
ovaries. Overall, the female reproductive system's monthly rhythmic functioning is 
totally dependent on the changing concentrations of these two steroid honnones. 12 
Estrogen and progesterone interact to influence the levels of the gonadotropins, as well as 
affecting the tissues that secrete them. In turn, the gonadotropins affect the activity and 
tissues involved with estrogen and progesterone production. 
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Each month, a small amount of the hormone relaxin is produced by the corpus 
luteum. IO,13 It has also been found to be produced in the mammary glands of non-
pregnant women. 13 Relaxin appears to be progesterone-dependent in the endometrium, 
and occurs in the highest levels during pregnancy. 
Hormonal Cycle Interrelations 
The term "female reproductive cycle" encompasses the menstrual and ovarian 
cycles and the hormonal changes that regulate them.1O They are both controlled by the 
hormone GnRH which promotes the release of FSH and LH from the anterior pituitary. 
During menstruation, the beginning of the cycle, the secondary follicles in the 
ovaries are maturing and beginning to secrete estrogen and inhibin, a hormone that 
inhibits the secretion of FSH and some LH.IO,II The initial secretion of estrogen by the 
growing follicles is stimulated by FSH. The secretion of LH causes the follicles to 
develop further. The full secretion of estrogen from the follicles instigates ovulation, 
promotes the formation of the corpus luteum, and stimulates the production of estrogen, 
progesterone, inhibin, and relaxin by the corpus luteum. 
When one of the follicles becomes dominant, the other follicles stop growing 
secondary to the decreased secretion of FSH by the anterior pituitary gland. 10,1 1 Since the 
secondary follicles cease to secrete inhibin, the LH levels begin to rise, causing the 
dominant follicle to continue to produce increased amounts of estrogen. During the end 
of the preovulatory or proliferative phase, the high levels of estrogen exert a positive 
feedback effect on LH and GnRH, resulting ultimately in ovulation. Specifically, when 
estrogen levels are of sufficient concentration in the blood, the hypothalamus is 
stimulated to release more GnRH and the anterior pituitary is stimulated to produce more 
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LH. GnRH promotes the release ofFSH and increased LH. This surge ofLH causes the 
rupture of the fully mature, dominant follicle and the expulsion of a secondary oocyte 
(ovulation) . . 
The secretory phase begins after ovulation and depends upon progesterone 
secreted by the corpus luteum.9,10 Secretions ofLH stimulate the ruptured mature follicle 
to develop into the corpus luteum.9-11 The corpus luteum then serves to secrete 
increasing amounts of progesterone and a lesser amount of estrogen. Contractions of 
smooth muscle cells in the uterus (myometrium) are inhibited by progesterone in order to 
prevent interference with a possible implantation of an embryo. When failure of 
fertilization and implantation of the ovum occurs, the corpus luteum ceases its function 
after approximately fourteen days.9 The levels of estrogen and progesterone in the blood 
therefore decrease rapidly. The endometrium developed secondary to these hormones is 
no longer sustained, and thus begins necrosis. This brings the cycle to its end, and once 
again back to the menstrual phase with the onset ofmenses.8-10 Figure 1 demonstrates the 
relationships of the hormones throughout the cycle .. 
. Relaxin also serves to relax the uterus by inhibiting contractions of the smooth 
muscle, as well as the pubic symphysis. 10,13 During pregnancy, it causes growth of the 
interpubic ligament, modest relaxation of the pelvic ligaments, and the sacroiliac joint 
increases in flexibility during late pregnancy. 13 Relaxin will be discussed in further detail 
in a following chapter. 
Other functions of the estrogen produced and secreted by the follicles include 
promoting the development and maintenance of the reproductive structures, secondary 
sex characteristics, and the breasts. Secondary sex characteristics include distribution of 
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adipose tissue, change in voice pitch, broadening of the pelvis, and hair growth on the 
head and body.lo Estrogen also controls fluid and electrolyte balance, increases protein 
metabolism, decreases blood cholesterol, causes an increase in bone formation by 
facilitation of calcium uptake, promotes closing of epiphyseal (growth) plates in long 
bones, and increases capillary wall strength.8,1O,12 Progesterone, on the other hand, is 
secreted mostly by the corpus luteum and acts synergistically with estrogen to prepare the 
endometrium for a fertilized ovum and the breasts (mammary glands) for the secretion of 
milk. It is important to note that high levels of progesterone inhibit the secretion of 
GnRH from the hypothalamus and LH from the pituitary gland (negative feedback).8,10 
In conclusion, the female reproductive system involves the hypothalamus, 
anterior pituitary gland, and the reproductive organs in a complex interaction. As the 
hormones are produced and secreted from these structures, they affect the functioning of 
the cycles that occur on a monthly schedule after the female begins menstruating during 
puberty. The chemicals' influence extends beyond the development and maintenance of 
the reproductive organs to affect other structures of the body as well. A balance of the 
interactions is necessary for a normal, healthy, and viable reproductive system. 
Relaxin's hormonal relations to the female reproductive system have been briefly 
discussed in this chapter. Relaxin has been the object of much research concerning low 
back pain and injuries in women, and may be an important factor to consider when 
studying these occurrences. 
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CHAPTER III 
RELAXIN 
As mentioned in a previous chapter, relaxin is a hormone produced by the female 
reproductive system. Because of its association with the relaxation of ligaments in the 
pelvis during pregnancy, the hormone's influence on back pain has been a focus of 
research. 14-16 This section will continue the discussion of relaxin and the research 
involving its possible roles in lumbopelvic pain. 
The knowledge of the structure and function of human relaxin is still limited. 14 It 
is a polypeptide hormone that was formerly held to be associated with pregnancy. IS It 
was also believed to be of luteal origin. Production of relaxin has been localized in the 
ovaries, uterus, and placenta. 17 Relaxin's main influence is on labor, but it has also been 
associated with symptom-giving pelvic girdkrelaxation during pregnancy. IS Elevated 
serum levels of this hormone have also been noted during the luteal phase of the 
menstrual cycle in non-pregnant women. 
Relaxin and Pelvic Pain 
Bryant et al. 17 conducted a study on serum relaxin immunoactivity. 
Immunoassays involve measuring protein and protein-bound molecules involved in the 
reaction of an antigen with its specific antibody and the concentrations of substances, 
such as protein-bound hormones, in the blood plasma. 18 The researchers found relaxin 
immunoactivity to be high during menstruation and decreased until the middle of the 
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proliferative phase when a peak, equal in amplitude to the peak during menstruation, 
occurred. 17 Relaxin immunoassay remained fairly constant throughout the LH surge 
(prior to ovulation), and as LH dropped during ovulation, relaxin increased reaching 
maximal levels for the entire cycle. Relaxin then decreased to low levels until menses 
began once again (refer to Figure 1). The research concluded that, at any given time, the 
total relaxin immunoactivity may originate from the follicle, corpus luteum, uterus, or 
any combination thereof. 
A study using homologous enzyme-linked immunosorbent assay for high 
sensitivity human relaxin in non-pregnant women was conducted by Wreje et al. 15 This 
research reported that women with posterior pelvic pain had statistically significant levels 
of detectable serum relaxin more frequently than did healthy women (p<O.OOI). Also, 
women using oral contraceptives tended to have detectable mean values of relaxin that 
were higher than during the normal menstrual cycle, indicating that oral contraceptives 
may induce a change in secretion of relaxin. This finding also points to a source other 
than the corpus luteum for relaxin, since no corpus luteum is formed with the use of oral 
contraceptives. Women who had a history of back pain with pregnancy reported a 
relapse with oral contraceptive use. The researchers did state, however, that the increased 
levels of relaxin in patients with posterior pelvic pain needs further exploration. 
Research has also been done relating serum relaxin levels during pregnancy to 
low back pain. 14-16 One such study found a significant correlation between the amount of 
relaxin and onset of pain during pregnancy in the pubic symphysis and trochanteric 
region, but no correlation was found between back pain locati~n and mean relaxin 
levels. 14 The combination of sacral pain and symphyseal or lumbar pain showed a 
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significant correlation with mean relaxin values, however. There was also an increase in 
symptoms/pain levels with increased relaxin concentrations. An additional study 
reported increased levels of serum relaxin in women with disabling pelvic pain in the 
latter half of the pregnancy term. IS 
Contrarily, another resource found no significant difference in concentrations of 
relaxin during the thirtieth week of pregnancy in women with disabling pelvic pain as 
compared with pregnant women experiencing no pelvic pain. 16 Neither did they find an 
association between relaxin in symptom-giving pelvic relaxation during human 
pregnancy. However, two biologically and immunologically active relaxin hormones 
exist; this study used an assay that was only available for one of the two. There may be a 
possible role for the other in human pelvic girdle relaxation. 
Collagen Metabolism 
Weiss et al. I9 researched relaxin and collagen metabolism. They reported the 
influences of relaxin on the pubic symphysis in the mouse. In mice treated with relaxin 
and a form of estrogen (estradiol), the water content, dry weight, and the acid soluble 
collagen increased in relation to total collagen. Collagenase concentration was also 
slightly greater with relaxin and estradiol treatment; collagenase was also found to be 
present in non-pregnant mice. Estradiol and relaxin work synergistically and there is 
evidence of increased activity of collagenase after the administration of the two 
hormones. Basically, in the pubic symphysis, relaxin activates the collagenolytic system, 
thus there is a breakdown of the collagen. This may have implications on pelvic girdle 
relaxation and/or possible instabilities. 
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There is still relatively little known about the human hormone relaxin. Several 
studies have been done on non-human sources of relaxin, and its role in humans is not yet 
understood fully. In the research conducted thus far, contradictions exist and research is 
rather inconclusive. In addition to relaxin, there are other possible hormonal influences 
on LBP in the female athlete resulting from the remaining female steroid hormones. In 
the following chapter, the findings will be discussed on the relationship between the 
reproductive hormones and LBP. 
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CHAPTER IV 
THE HORMONAL CYCLE INFLUENCE ON LOW BACK PAIN 
The occurrence of low back pain has been well documented in various sportS.3,7,20 
With increased studies of low back pain (LBP) in athletes, it has been demonstrated that 
women tend to require treatment or have a higher prevalence of LBP more often than 
men.3,7 The female sex hormones have been suggested to affect the risk of low back 
pain2o; this observation is made secondary to the fact that low back pain is commonly 
seen during pregnancy.7,20-22 "Structurally, the female pelvis is shorter and wider than the 
male pelvis. The hormonal changes of menses and pregnancy render the female pelvis 
slightly more mobile, and it has been suggested that this results in increased vulnerability 
to the sacroiliac joint. ,,23(pI61) 
Because low back pain often occurs early on in pregnancy, it cannot be explained 
solely by an increase in mechanical stress?l Studies have shown an increased laxity and 
flexibility in pelvic ligaments and joints during pregnancy, pointing to hormonal factors 
as probable causes oflumbopelvic pain, though the exact mechanisms are not known.7,21 
An estrogen induced change in relaxin receptor sensitivity has been suggested as an 
instigator for increased lumbopelvic pain.24 Additionally, estrogen receptors have been 
found in muscles and ligaments of the female pelvis, though not in erector spinae 
muscles, and there is increased mobility in the sacroiliac joint during and after 
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pregnancy?2 Luteal and placental relaxin have suggested effects on the pelvic and low 
back ligaments, also. 
Oral Contraceptives 
Many of the studies conducted on women and low back pain have focused not 
only on the menstrual cycle influences, but also the effects of oral contraceptives.7,2o-22 
Therefore, it is important to understand the mechanism of action of the oral 
contraceptives. 1 This will be briefly explained for the purposes of this and following 
chapters. 
Oral contraceptives contain synthetic steroids with estrogenic and progestogenic 
effects which inhibit the pituitary FSH and LH production by a negative feedback 
mechanism. 1 This, in turn, prohibits follicular growth, ovulation, and the production of a 
corpus luteum. The exogenous steroids continue to induce endometrial growth and 
shedding will occur when oral contraceptive intake is ceased, usually for one week every 
four weeks. 
Research 
One study looked at the effects of both the menstrual cycle and oral 
contraceptive factors on low back pain in female soccer players.2o This study reported 
that all the subjects had normal orthoneurological findings during the baseline exam. 
Low back pain and lumbosacral region "tiredness" were the most common symptoms. 
Their finding was that neither occurrence nor severity of low back pain varied 
consistently during the menstrual cycle, and the average number of days with LBP was 
the same between those using and those not using oral contraceptives. The authors 
concluded that the results could have been due to the hormonal fluctuations being too 
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small to affect spinal structures or that the exposure to repetitive, substantial stress in 
sports may have hidden any hormonal components. The authors referred to the high 
prevalence of LBP found in women's sports and the incidence of insidious onset pain. 
Because some back pain is of gradual onset, it cannot be explained by traumatic factors 
alone. The theory on the influence of hormonal factors considers the large variation in the 
serum concentrations of sex steroids during the menstrual cycle, and the possible effect 
on spinal and pelvic tissues. Also, the prevalence of back pain may vary during the 
menstrual cycle and may differ between women who use oral contraceptives and those 
who do not. The authors' suggestions for further research to better identify hormonal 
influences on LBP included minimizing the stress on the spine by studying more 
sedentary women with light occupations. 
It has been proposed that both endogenous and exogenous female sex steroids 
may have an influence on the risk ofLBP.7 Specifically, oral contraceptives have been 
suggested to increase the risk of LBP. Two suggested theories on oral contraceptive use 
and its effects on LBP secondary to estrogen content are the following: 1) oral 
contraceptives inhibit the release of the gonadotropins, therefore the concentration of sex 
hormones are more stable with the use of oral contraceptives, leading to a decreased risk 
of LBP or 2) oral contraceptive steroid hormones may have a more pronounced effect on 
pelvic and spinal structures than endogenous hormones and may thus increase the risk of 
LBP. 
A study was conducted by Brynhildsen et al. 7 on the prevalence of LBP between 
oral contraceptive users and nonusers and the variance between women in differing 
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sports. The study found the average prevalence of LBP was significantly higher in the 
athletic groups than the controls, but the occurrences of back pain within each group were 
similar between oral contraceptive users and nonusers. Therefore, this study does not 
support the theory that LBP is affected by the use of oral contraceptives. The authors 
proposed that the influence of physical activity and repetitive stress exposure is likely 
more important. In addition, women in elite-level sports are probably more conscientious 
of their health and more likely to report symptoms. 
On a different note, some of the subjects in this particular study chose to 
discontinue oral contraceptive use secondary to LBP. 7 About forty percent of those 
subjects reported a decrease in symptoms, however, the numbers were too few to 
significantly affect the results. Another study reported that several physicians, 
physiotherapists, and midwives hold the belief that oral contraceptive use increases the 
risk of LBP. 22 Even with a lack of evidence, many still recommended discontinuance 
with low back pain occurrence. This revealed an attitude toward oral contraceptives and 
LBP, even though, at this time, research does not support a correlation. 
Research on hormone replacement therapy (HRT) and low back pain in 
postmenopausal women theorized that, founded on clinical experience, steroid hormones 
affect joints and ligaments leading to symphysiolysis and LBP?! The study found that a 
significantly higher prevalence of current LBP occurred in HRT subjects as compared to 
nonusers. The HRT subjects also tended to report more frequent episodes and longer 
durations. Neither the exercise status nor the history of previous oral contraceptive use 
affected the occurrence of current low back problems in HRT subjects. However, parous 
women that experienced LBP during pregnancy had a greater prevalence of current LBP 
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than women without back pain during gestation when using HR T. The study also 
reported that radiological and pathologicallbiomechanical studies have shown effects of 
pregnancy on pelvic joints. 
So far, available research does not support any relationship between the menstrual 
cycle or oral contraceptive use and LBP. One factor to consider is that it is difficult to 
find a single cause for LBP, especially in sports, due to the differing biomechanical 
stresses. 7 At this time, very little has been studied on this topic, and more attention is 
necessary before drawing any further conclusions. Attention in research has also been 
drawn to other injuries that occur in female athletes and the possible hormonal influences. 
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CHAPTER V 
INJURIES IN THE FEMALE ATHLETE 
As the number of female athletic participants continues to rise in leisure as well as 
competitive sports, the amount of training and competition these women participate in 
increases, also. Women's sports are spreading to encompass more and more competitive 
athletics that were previously considered "male dominated." Inherent to the nature of 
athletics, the risk of injuries correlates to the amount of athletic activity. 
Compared to their male counterparts in comparable sporting activities, a greater 
number of injuries has been found to occur in the female athletic popUlation. 1,3"6 This 
observation has prompted the need for more research into this topic and speculation as to 
the possible causes. 
Research 
Several studies have been conducted on the types of injuries incurred by athletes. 
One study done by Nadler et al.3 on LBP in college athletes showed that significantly 
more women required treatment for low back pain than did the men involved in the study 
(15% of the women, 6% of the men). An additional study of the sacroiliac joint and LBP 
in college students by Gemmell and Jacobson25 found that 23.1 % of males and 38.9% of 
females reported a history of LBP, again a significant difference. Still other studies have 
found a significant difference in lower extremity injuries between male and female 
basketball players.4,5 In fact, one study found the risk for females was 2.5 times greater 
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for season-ending injuries and 3.54 times higher for injuries requiring orthopedic 
surgery.4 
Causes 
It has been suggested that a possible cause for the difference in injuries may be 
related to the structural variations in men and women.4-6,20 Specifically, changes that 
occur in females during puberty alter the structure of the pelvis.6 Females experience a 
widening of the pelvis in relation to the waist and shoulders, which causes a varus 
position at the hips and an increased valgus position at the knees. The broader pelvis is 
often associated with a greater anteversion of the femoral head, and genu valgus causes a 
higher Q angle (quadriceps pull). Overuse injuries at the hip, knee, and ankle in female 
athletes have been blamed on these structural changes. 
Other possible causes of the increased incidence of injuries are a lack of proper 
conditioning6,26 and inappropriately matched competition.6 Recommendations to 
decrease the risk of injury include appropriate warm-up and stretching along with prior 
conditioning and skill development.6,26 Also, knowledge of the sport and its rules is 
beneficial to reducing injury risk.6 
Speculation as to the particular influences on injury rates includes the possible 
effects of female steroid hormones. In contrast to men, women experience a regular, 
monthly endocrine cycle. 1 Several studies have found differences in athletic performance 
and/or the incidence of injuries in different phases of the menstrual cycle. 1,2,5,26,27 
Hormonal Influences 
"The female athlete, during her reproductive years, has a complex and ever-
changing milieu of female steroid hormones, whether it is the endogenous variations of 
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[ estrogen] and progesterone of a regular menstrual cycle, or the exogenous synthetic 
hormones of the oral contraceptives. ,,2(p400) Both estrogens and progesterones have 
physiological actions, but little is known about the effects of specific female steroid 
hormones on athletic perfomance.2 Although the effect of the menstrual cycle varies 
greatly from one individual to another,2 several studies have found that the risk of injury 
is greater premenstrually and during menstruation than other phases ofthe cycle. 1,2,26,27 
This was especially true in women who experienced premenstrual symptoms (PMS), such . 
as fatigue, irritability, insomnia, headache, cramps, mastodynia, and fluid retention in the 
abdomen and breasts. 1,2,26 It has been suggested that the symptoms related to PMS 
decrease coordination and may adversely influence overall performance. I This is 
supported by the findings that women who do not experience PMS or are on oral 
contraceptives, which tend to reduce premenstrual symptoms, do not show an increased 
risk for injuries during any cycle phase. 1,2,26 
Studies have shown the effects of the menstrual cycle on athletic performance to 
be different during varying phases in the cycle?,27 Lebrun et al.27 conducted a study of 
the effects ofthe menstrual cycle on aerobic capacity, anaerobic capacity, isokinetic 
strength, and high intensity endurance. They reported a slight, deleterious influence on 
aerobic capacity during the mid-luteal phase as compared to the early follicular phase. 
However, the cycle phase had no significant impact on the majority of other performance 
tests or cardiorespiratory variables measured. 
Other research reports that females, especially those with premenstrual symptoms, 
have a decrement in motor performance during the premenstrual phase and performed 
best during menstruation or immediately thereafter? It is also suggested that throughout 
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the normal menstrual cycle, subtle physiological changes may occur in ventilation, 
vascular volume dynamics, thermoregulation, and substrate metabolism. \,2 
Effects of Oral Contraceptives 
As mentioned before, the use of oral contraceptives frequently diminishes the 
premenstrual symptoms and also appears to alleviate the negative effects of the menstrual 
cycle on athletic performance. Since oral contraceptive steroids significantly affect the 
hormone cycle through the suppression of the pituitary gland, it is reasonable to assume 
they also have an effect on athletic performance, when taking into account the normal 
menstrual cycle influences. \ In fact, the administration of oral contraceptives has been 
found to cancel the fall in physical fitness levels during the premenstrual phase. Oral 
contraceptives tend to decrease the weight gain secondary to water retention as well as 
reduce menstrual blood loss and increase the iron-binding capacity of the blood. These 
are important factors because many women experience a weight gain of 1 to 2 kg during 
the luteal phase which can cause a drop in a runner's efficiency by 2-4%; reduced blood 
loss helps to reduce the anemic effect which influences the oxygen transport to muscles. 
The more optimal oxygen transport lowers the risk of muscle injury since muscles are 
more likely to be injured when working anaerobically. 
Oral contraceptives may also prevent excess bone loss secondary to amenorrhea, 
which has been linked to stress fractures and traumatic fractures in females with 
ovulatory disturbances.! It has been shown that strenuous exercise affects the menstrual 
cycle by causing menstrual disorders associated with decreased progesterone produced 
during ovulation and lower estrogen levels throughout the cycl~. The subsequent 
increase in bone loss (secondary to loss of estrogenic effects), therefore, causes greater 
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chances of sustaining fractures. Oral contraceptives regulate the hormones and the 
menstrual cycle. 
However, administering oral contraceptives to athletes should be cautionary since 
each individual may vary in response to the exogenous hormones and oral contraceptives 
may cause undesirable effects on aerobic capacity, muscle strength, and endurance.2 
Another precaution is associated with the fact that hormonal changes during pregnancy 
influence ligament laxity, and it is suggested that oral contraceptives have a similar 
influence. I This creates a greater range of movement and thus a higher risk of injury. 
Researchers do not happen to agree on either the qualitative or directional effects of oral 
contraceptives on various physiological tests? The actual preventive effects of oral 
contraceptives on traumatic injury rates needs further research?6 
Since women's sports continue to gain interest and popularity, it is important to 
recognize the possibility and frequency of injuries. Women appear to have an increased 
risk and rate of injuries. Very little is yet known as to why this phenomenon occurs, 
though several speculations have been made, from structural differences to hormonal 
influences. More research and attention is necessary, and crucial, in this area of women's 
health in order to gain insight into treatment and prevention. 
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CHAPTER VI 
CONCLUSION 
When treating the female athlete, either post-injury or preventatively, it is 
necessary to realize the structural and hormonal influences. As females differ from 
males, and from one another, treatment approaches should be tailored with the individual 
in mind. A detailed history should be taken including information about the menstrual 
cycle onset, duration, and regularity, presence of premenstrual symptoms, any differences 
or abnormalities in the cycle characteristics, parity, and if the female is using any 
exogenous hormones. The types and intensity of activities should also be taken into 
consideration. 
If treating the athletic population, or any particular population for that matter, it is 
crucial to have knowledge of the current literature. Though more research is obviously 
necessary before any definite conclusions may be drawn as to the influences affecting 
low back (lumbopelvic) pain and other injuries occurring in the female athlete, some 
apparent correlations exist involving the female reproductive cycle hormones. There are 
obvious differences in structure between males and females, but this alone does not 
explain the greater number of traumatic injuries that female athletes suffer. At this time, 
limited studies have been performed, but finally there is increasing interest in the female 
athlete as a separate entity from males. With more research, improved understanding, 
training, prevention, and treatment can ensue. 
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